What it does: Manufactures pharmaceutical products.
Mission: We believe that our mission is to provide high-quality and innovative medicines to people in the world by leveraging our strengths fully with our vision of “Reaching People. Touching Lives.”
Size and presence: Around 37,000 globally.
Best known for: Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. We are the largest pharmaceutical company in India.
The good bits: Good teams with a very good cohesive work environment.
The not so good bits: Workload can be too demanding sometimes.
Sun Pharmaceuticals was founded by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five products to treat psychiatry ailments. Cardiology products were introduced in 1987 followed by gastroenterology products in 1989. Today it is ranked No.1 by prescriptions with 9 different classes of doctors in India and a market leader in cardiology, gastroenterology, ortho, diabetology, dermatology, urology, and vitamins / minerals / nutrients.
The 2014 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 4th largest specialty generic company globally.
Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).
Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.
At Sun Pharma, we have found strength in our diversity, imbued by our culture of mutual respect, empathy, and adhering to the highest ethical standards. Our approach and culture is represented through Sunology: the Sun Pharma way of life. Humility, Integrity, Passion & Innovation together form Sunology – a combination of two words, Sun & Ideology. We encourage our employees to personify these ideologies, as they form the cornerstone of everything we create and value as an organisation. We are proud that our global workforce is bound together by our common values of quality, reliability, consistency, trust, and innovation. These values form the core of our culture and steer us towards our vision.
Sun pharma never ever takes a single penny for job. Neither in terms of refundable money not in terms of non-refundable money. Keep this in mind.
Sun pharma recruits through campus (through written and rounds of interview) like IIT, NIPER, DIPSAR etc. (If you’re fresher)
If you're experienced contact HR via LinkedIn, if you don't have direct connections. Send them your updated resume. (You can also contact on of the current employee to talk to HR for you formally).
If you did Internship in SUN then you can contact to your Reporting Manager and he will suggest you what to do next.
Finally, of you're shortlisted than either an interview will be on Skype/phone or a face to face interview at the decided location.
We attribute our growth and success to our over 35,000 strong multi-cultural workforce from over 50 different nationalities. Our team has taken Sun Pharma to the heights that it has scaled and are now working to take it further up on its high growth trajectory.
Our people are our most valuable asset. Our culturally diverse workforce is one of our biggest strengths and the rich experience they bring, across varied skill-sets and backgrounds, is invaluable. We are proud that our global workforce is bound together by our common values.
Average Sun Pharmaceutical Industries Fresher salary in India is ₹ 1.7 Lakhs per year for employees with less than 1 year of experience. Fresher salary at Sun Pharmaceutical Industries ranges between ₹ 0.2 Lakhs to ₹ 2.5 Lakhs per year.
Our Malaria Elimination Demonstration Project (MEDP) is a first-of-its-kind Public-Private partnership between the Indian Council of Medical Research (ICMR), Government of Madhya Pradesh (GoMP), and the Foundation for Disease Elimination and Control of India (FDEC India). FDEC India was established by Sun Pharmaceutical Industries Ltd. as a not-for-profit entity. The MEDP aims to eliminate Malaria from 1,233 villages of the Mandla district.
Our Mobile Healthcare Units (MHUs) deliver primary healthcare services to over 650,000 people located around areas close to our manufacturing plants and other establishments. These MHUs serve a mix of rural and underserved populations, visiting villages to provide treatment for common ailments, conduct pathological tests, enable referrals, and provide free medicines. This project is implemented in India through Sun Pharma Community Healthcare Society in the states of Punjab, Himachal Pradesh, Gujarat, Maharashtra, Madhya Pradesh, Tamil Nadu and Sikkim.
We develop model schools in and around our served communities, enabling and empowering rural school students to access and enjoy equal educational and development opportunities. Apart from building robust infrastructure, we help to implement technology-based learning programmes in schools. We also organise and support various co-curricular activities and related programmes, as operated through schools and educational institutions, located near our areas of operations.
We support and encourage provision of safe drinking water, adequate sanitation, and easily accessible hygiene services. Towards this end, we provide access to clean drinking water in villages, construct good quality individual toilets and implement effective behaviour change programmes.
The Sun Pharma Science Foundation is an independent non-profit organisation, registered under the Societies Act. Dedicated to promoting scientific endeavours in India, the Foundation encourages and rewards excellence in the medical and pharmaceutical sciences while channelling national and international knowledge and expertise in all subjects connected with the treatment of diseases that afflict humanity at large.
At Sun Pharma, we remain fully committed to achieving excellence through our Environmental, Health & Safety (EHS) programmes. Conducting our activities in a responsible, proactive manner is a core focus of our operations and culture. As a part of this commitment, our EHS Policy provides for the creation of a safe and healthy workplace and a clean environment for all employees and our served
communities. Aiming for, and adhering to, the highest international standards in plant design, equipment selection, maintenance, and operations, our EHS policy is a core commitment of our operations. We have established an ISO14001:2015 compliant Environmental Management System and ISO 45001:2018 compliant Occupational Health and Safety Management System at our key manufacturing facilities.
Sun Pharmaceutical Industries — along with seven of its executives including Dilip Shanghvi (managing director) and Sudhir Valia (director) — has settled a pending dispute with the Securities and Exchange Board of India (Sebi) by agreeing to pay a cumulative penalty of Rs 2.92 crore.Sun Pharma has agreed to pay Rs 56 lakh, while Shanghvi will pay Rs 62.3 lakh, and Valia Rs 37.4 lakh. Other individuals have agreed to pay between Rs 18.5 lakh and Rs 37.4 lakh.